Contribute Try STAT+ Today

WASHINGTON — In the Obama administration’s final days, the National Cancer Institute is establishing an ambitious new program designed to allow scientists to more quickly access new drugs and compounds for novel research.

One of the last achievements of Vice President Joe Biden’s cancer moonshot initiative before he leaves office, the program was unveiled Wednesday and will begin as an agreement between the institute and six drug companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Biden’s “moonshot” is not disimilar to the approach of past politicians with their proclaimed, “war on cancer”. At best it is misguided. While we need drugs to help people live longer, the battle is essentially lost and has been for decades. We are the throwing money at the disease; it looks good, and it feels good but it won’t stop the disease. The practice just fuels the economy by putting money in the hands of companies with cashflow already overflowing. Instead, Put the money in the hands of those struggling to find the CAUSES of cancer. Preventive medicine is always the better route. Microbes, particularly viruses have been found “causitive” yet no BIG money flows into vaccine manufacture (except for HPV which took 70 yrs even though its role in cancer was known). A vaccine against the HERPES group should be a first priority.

  • Without Novartis on board this will never make it
    They need to roster the big players in Oncology and then move it out to the NCI institutions
    The institutions will accept any offer as long as it is painless and fast. The 6 out of 46 PharmaCos are a good start now lets see how NCI messes it up
    Dr D (surgical oncologist)

Comments are closed.